50.020836, 19.880947
PDF / print export
Selvita
Krakow, Poland
- Verified lead
- Bogusław Sieczkowski
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Integrated Drug Discovery and Development
- Review cycle
- May 2026
- Full address
- ul. Podole 79, 30-394 Krakow, Poland
- Site coordinates
- 50.020836, 19.880947
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Selvita management profile confirming Boguslaw Sieczkowski as CEO.
- Editorial note
- Multi-site discovery engine with medicinal chemistry, DMPK, and biology labs positioned for German pharma partnering and preclinical throughput.
Integrated Drug Discovery and Development
Drug Discovery and Development Platform
Multi-site discovery engine with medicinal chemistry, DMPK, and biology labs positioned for German pharma partnering and preclinical throughput.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Multi-site discovery engine with medicinal chemistry, DMPK, and biology labs positioned for German pharma partnering and preclinical throughput.
- Lead
- Bogusław Sieczkowski (verified ↗)
- Address
- ul. Podole 79, 30-394 Krakow, Poland (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 14 Mar 2026 (3mo ago)
- Scale
- Multi-site research services platform
- Capabilities
- Drug Discovery Services · Preclinical Development · Integrated Chemistry and Biology
- Founded
- 2007
- Headcount
- 501-1000
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Bogusław Sieczkowski
Chief Executive Officer
Full addressul. Podole 79, 30-394 Krakow, Poland
Site coordinates50.020836, 19.880947
Review cycleMay 2026
Physical site source
Official Selvita contact page listing ul. Podole 79, Krakow headquarters.
Open sourceMulti-site research services platform
Krakow, Poland. Integrated Drug Discovery and Development. Review completed on 14 Mar 2026.
Polish and EU research and pharmaceutical oversight
Drug Discovery and Development Platform
Integrated Drug Discovery and Development
Multi-site discovery engine with medicinal chemistry, DMPK, and biology labs positioned for German pharma partnering and preclinical throughput.
Related companies
Editorial note
Selvita is mapped as a Polish R&D anchor with downstream cluster relevance to German pharmaceutical and industrial-biotech decision nodes.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Drug Discovery Services
Preclinical Development
Integrated Chemistry and Biology
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Equipment detail not disclosed in the current record.
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
14 Mar 2026: Executive identity confirmed via official management disclosure.
14 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Selvita located?
- Selvita operates from ul. Podole 79, 30-394 Krakow, Poland, Krakow, Poland.
- Who runs Selvita?
- Selvita is led by Bogusław Sieczkowski, Chief Executive Officer. Verified 14 Mar 2026.
- What does Selvita do?
- Multi-site discovery engine with medicinal chemistry, DMPK, and biology labs positioned for German pharma partnering and preclinical throughput. Core capabilities: Drug Discovery Services, Preclinical Development, Integrated Chemistry and Biology.
Editorial context
Related technical briefs
Briefs that name Krakow as a covered market or city.